Skip to main content
. 2016 May 6;14:125. doi: 10.1186/s12967-016-0877-x

Fig. 3.

Fig. 3

Comparison of Kaplan-Meier curves for progression-free survival according to GNAS mutational status in the prospective cohort (metronomic capecitabine and bevacizumab)